In breast cancer and normal estrogen target tissues, estrogen receptor-a (ERa) signaling results in the establishment of spatiotemporal patterns of gene expression. Whereas primary target gene regulation by ERa involves recruitment of coregulatory proteins, coactivators, or corepressors, activation of these downstream promoters by receptor signaling may also involve partnership of ERa with other transcription factors. By using an integrated, genome-wide approach that involves ChIP-chip and computational modeling, we uncovered 13 ERa-responsive promoters containing both ERa and c-MYC binding elements located within close proximity (13-214 bp) to each other. Estrogen stimulation enhanced the c-MYCERa interaction and facilitated the association of ERa, c-MYC, and the coactivator TRRAP with these estrogen-responsive promoters, resulting in chromatin remodeling and increased transcription. These results suggest that ERa and c-MYC physically interact to stabilize the ERa-coactivator complex, thereby permitting other signal transduction pathways to fine-tune estrogen-mediated signaling networks.
Introduction
Estrogen plays pivotal roles in human physiology and breast cancer genesis and progression (McDonnell and Norris, 2002) . The biological actions of estrogen are mediated through binding to estrogen receptors (ERs), ERa, and ERb, which belong to the nuclear receptor superfamily of transcription factors. Intensive studies have revealed multiple mechanisms by which these receptors activate or repress their target genes. Upon ligand activation, ERa-mediated transcription is through binding directly to specific estrogen response elements (EREs) in the promoters of responsive genes (Metivier et al., 2003) or via protein-protein interaction with other promoter bound transcription factors, such as SP1 (Saville et al., 2000) , AP1 (DeNardo et al., 2005) , or NF-kB (Stein and Yang, 1995) . In either case, coactivators or corepressors are further recruited to form a functional receptor complex that specifies transcriptional activities of downstream targets.
Upregulation or downregulation of receptor target genes may occur through complex chromatin remodeling, both in and around the responsive promoters (Metivier et al., 2003; Xu and Li, 2003) , and different combinations of histone modifications may act synergistically or antagonistically to affect gene expression (Jenuwein and Allis, 2001) . For example, acetylation of lysine 9 at histone H3 (H3-K9) is linked to transcriptional activation (Roh et al., 2005) , whereas dimethylation of the same lysine seems to specify transcriptional repression (Peters et al., 2003) . In this regard, nuclear coregulators, which often possess chromatin modulating activities, appear to act cooperatively with ERa to establish patterns of gene expression and thus provide considerable functional flexibility in specifying transcriptional activation or repression (McKenna and O'Malley, 2002) .
In addition to gene regulation by nuclear ERa, evidence exists for a membrane form of the receptor that may serve to mediate the activities of other intracellular signaling pathways and potentially contribute to both genomic and nongenomic effects of estrogen in various target tissues (Revankar et al., 2005) . In this regard, transactivational effects of ERa may also be regulated via independent trans-regulatory partners, a much less understood and largely unexplored process. However, given the fact that crosstalk with other signal transduction pathways may allow ERa to regulate gene expression via association with additional transcription factors (Carroll et al., 2005; DeNardo et al., 2005; Saville et al., 2000; Stein and Yang, 1995) , specific transcription factor partners could be involved in coregulating gene activities via direct binding to their consensus sequences in the ERa-responsive promoters.
In the present study, we used a genome-wide approach called ChIP-chip (Ren et al., 2000) to identify direct ERa target genes. Chromatin immunoprecipitation of specific protein/DNA complexes was utilized to probe a promoter CpG island microarray panel (Heisler et al., 2005) . Based on recent studies demonstrating a correlation between acetylation and dimethylation at H3-K9 with gene activation and repression, respectively (Kondo et al., 2004; Peters et al., 2003; Peterson and Laniel, 2004; Roh et al., 2005) , we first classified the ERaresponsive promoters into acetylated and methylated groups. Computational modeling with classification and regression tree (CART) (Breiman et al., 1984) identified 7 cis-regulatory modules that discriminate acetylated promoters from methylated promoters and recognized putative transcription factor partners. Experimental validation of the computational findings further identified c-MYC as a positive regulator of the ERa-mediated transcriptional network. c-MYC is a well-characterized ERa target gene that plays a critical role in the ability of estrogen to enhance the proliferation of breast cancer cells. Upregulation of c-MYC by ERa resulted in further recruitment of this transcription factor partner to other ERa-responsive promoters and led to target gene activation. Our results demonstrate that integrative ChIP-chip and bioinformatics approaches can be used to interrogate combinatorial control of ERa-regulated transcription, a strategy that can be used to examine additional transcription factor partners.
Results

Histone Modifications Occur Near the Transcription Start Site of ERa-Responsive Promoters upon Estrogen Signaling
ChIP accompanied with microarray screening has become an important approach for comprehensive analysis of transcriptional regulation. We first studied dynamic changes in the chromatin landscape by using a smaller microarray platform of 192 arrayed elements for four known ERa-responsive promoters: progesterone receptor isoform B (PRB), c-MYC, BCL2, and ZNF217. MCF7 breast cancer cells were hormone-deprived for 4 days and then treated for 24 hr with 10 nM 17b-estradiol (E2). Antibodies against specific histone modifications (acetyl-H3-K9 and dimethyl-H3-K9) were used to immunoprecipitate DNAs for microarray hybridization ( Figure 1A ). For quality control, we tested the specificity of these antibodies, and the lowess-normalized microarray data further confirmed specific enrichment of immunoprecipitated DNAs (Figures 1B and 1C) . By using the microarray data, we generated a chromatin map spanning the 5 kb upstream and the 1 kb downstream regions from the transcription start site (TSS) of the four interrogating promoters based on the Ac/Me ratio (i.e., acetyl-H3-K9/dimethyl-H3-K9 (Kondo et al., 2003 (Kondo et al., , 2004 . Upon estrogen stimulation, we observed a shift of the Ac/Me ratio of chromatin profiles in the vicinity of the TSS in upregulated PRB, c-MYC, and BCL2 promoters (Figure 2 ). In this case, acquisition of acetylated histones (at lysine 9) and, at the same time, loss of methylated histones tended to occur in a more focal region (w1 kb) around the TSS, a process that may be facilitated by the interaction of ligand bound ERa with various chromatin-modulating proteins (Metzger et al., 2005; Yanagisawa et al., 2002) . Two additional regions, located 3 to 5 kb upstream of the PRB TSS and 2.5 to 3.5 kb upstream of the c-MYC TSS, Growing cells were crosslinked with formaldehyde, and the sonicated chromatin was immunoprecipitated with a specific antibody. The enriched DNAs were purified, fluorescently labeled, and cohybridized onto two microarray platforms (12K CGI array and CLM) along with an input sample that had been labeled with a different dye. The chromatin landscaping microarray (CLM) contains four known estrogen-responsive promoter regions, each spanning 5 kb upstream (P1 to P10 fragments) and 1 kb downstream (E1 and E2 fragments) of the transcription start site (arrow). (B) Quality control of CLM. The sonicated chromatin was immunoprecipitated with acetyl-H3-K9 antibody, labeled with Cy5, and cohybridized with Cy3-labeled input. The green spots of 16 repetitive sequences (in triplicate) indicated preferential hybridization with input and not immunoprecipitated DNA (Cy5:Cy3 ratio = 0.15). These data show that the antibody used was specific. (C) Antibody-specific enrichment in ChIPchip. Chromatin immunoprecipitated with ERa antibody was labeled with Cy5 and cohybridized with Cy3-labeled input. The Cy5:Cy3 ratio was log 2 transformed and plotted against the signal intensity (M/A plot). The wide spread of the ratios reflects specific enrichment during the immunoprecipitation. The lowess curve (blue line), with 20% of the data used at each point, was overlaid on the plot and used in intensity-dependent normalization. As a confirmation, the lowess curve estimated from the normalized data was nearly a straight line as shown in the lower panel. Similar results were obtained when the enriched immunoprecipitated targets were labeled with Cy3 and the input DNA was labeled with Cy5 ( Figure S1 ). also showed acquisition of more methylated and acetylated histones, respectively, but whether these regions contain functional cis-regulatory elements in response to estrogen stimulation remains to be investigated. Interestingly, we observed a wider spread of chromatin changes in a 6 kb region of the ZNF217 promoter (Figure 2) known to be downregulated by ERa. In this regard, the acquisition of more methylated histones is associated with transcriptional repression of this gene. This chromatin landscaping analysis thus provides an effective approach to assess transcriptional activities of ERaresponsive genes based on their altered chromatin profiles.
ChIP-Chip Analysis Reveals Concerted Action of ERa Binding and Histone Modifications in Responsive Promoters upon Estrogen Stimulation
We performed a series of ChIPs by using a specific antibody against ERa in MCF7 cells treated with E2 for 0, 3, 12, and 24 hr. The immunoprecipitated DNA was used to probe the 12K CGI microarray (Heisler et al., 2005) . Because many gene promoters are known to be located near or within CpG islands, this microarray panel is useful for finding new ERa-responsive promoters. We applied Significance Analysis of Microarrays (SAM) to define significant loci (7% false discovery rate), and 83% of these loci attained maximal ERa binding at 3 hr after E2 treatment. Hence, a total of 92 loci were identified as putative targets, which had enrichment signals of >2 at the 3 hr time point in two independent microarray experiments (see also the Supplemental Data, available with this article online, for computational analysis of these loci and Table S1 ). As shown in a heat map (Figure 3A) , maximal binding of ERa to these targets was observed at 3 hr after E2 treatment and returned to near basal levels at the 12 and 24 hr time periods. Minimal or no enrichment signal was observed for the no-antibody control, as compared to immunoprecipitated DNAs hybridized to positive targets (data not shown).
To determine whether these direct ERa target genes were transcriptionally activated or repressed by ligand bound ERa, we performed serial ChIP assays with antibodies against acetyl-and dimethyl-H3-K9 in MCF7 cells treated with E2 for 0, 3, 12, and 24 hr. The immunoprecipitated DNA was used to probe the same CGI microarray, and SAM was used to analyze the chromatin profiles of the 92 target genes. We were able to classify 40 acetylated and 28 methylated targets, suggesting that these targets were upregulated and downregulated by ligand bound ERa, respectively (see also the Supplemental Data for statistical analysis and Table S2 ). Consistent with the dynamic pattern of ERa binding, the levels of histone modifications (either acetylation or methylation) were maximal at 3 hr after treatment and returned to basal level by 12 and 24 hr ( Figures 3B and 3C ). The acetylated and methylated targets identified by SAM analysis were located preferentially at the top and the bottom parts of the heat map, ranked by the order of the Ac/Me ratio at the 3 hr time point ( Figure 3D ). The classification of ERa target genes was also supported by our global gene expression analysis, which showed a positive correlation between histone modification status (A) MCF7 cells were maintained in phenol red-free MEM supplemented with 3% charcoal-dextran FBS for 4 days and then were either left untreated or were treated with 10 nM 17b-estradiol (E2) for 24 hr. ChIP assays were performed with antibodies directed against acetyl-H3-K9 (Ac) and dimethyl-H3-K9 (Me), and the dye-coupled DNA was hybridized onto CLM. The microarray signals were determined as described in the Experimental Procedures, and the Ac/Me ratios were plotted for each ERa-responsive promoter region. (B) MCF7 cells grown as described above were either left untreated or were treated with 10 nM E2 for the indicated time periods. Total RNA was extracted, and the expression of PRB, c-MYC, BCL2, or ZNF217 genes was analyzed by quantitative RT-PCR. Each error bar represents standard deviation calculated from triplicates. The amplification of sample without reverse transcriptase (RT) served as the negative control. The asterisk indicates p < 0.05 (versus untreated cells).
(Ac/Me ratio) and transcriptional activity (p = 0.041, Fisher's exact test, Table S3 ).
To validate the microarray findings and determine the presence of ERa binding on promoter targets, we performed quantitative ChIP-polymerase chain reaction (PCR). Immunoprecipitated DNAs were amplified by using paired primers flanking the consensus sequences of EREs predicted by ERTargetDB . As shown in Figure 4A , eight loci with diverse enrichment signals (CCND1, c-MYC, RBBP8, CR2, THBS1, PTPN13, BCL11A, and PCDH9) were randomly selected from the 92 putative targets and independently confirmed as ERa-responsive promoters. All these loci showed higher levels (2-to 9-fold) of ERa binding after treating MCF7 cells with E2 for 3 hr. RASSF1A showed no binding of ERa in either condition (treated or control) and thus served as a negative control (data not shown).
To determine the level of transcription of these loci, ChIP was performed by using an antibody against RNA polymerase II (RNA Pol II) and was quantified by real-time PCR. Estradiol-enhanced RNA Pol II association was detected in CCND1, c-MYC, RBBP8, CR2, and THBS1 genes ( Figure 4B ). Although the degree of enhancement varied among the different promoters, the results demonstrate that E2-induced ERa binding positively regulates transcription of these genes. In contrast, E2 treatment did not promote RNA Pol II binding at PTPN13, BCL11A, and PCDH9. Because ligand bound ERa can recruit coactivators, including CBP and SRC-3, to specific chromatin regions for remodeling (McKenna and O'Malley, 2002) , we examined the association of these coactivators with the ERa-responsive promoters. In CCND1, RBBP8, and CR2, which all displayed enhanced RNA Pol II association after E2 treatment, CBP or SRC-3 was also recruited to these chromatin regions ( Figures  4C and 4D ). There was no change in CBP/SRC-3 binding at c-MYC, and CBP binding at THBS1 decreased, indicating that other coactivators may be recruited to these promoters after E2 treatment. In contrast, for those loci with no change in RNA Pol II binding, coactivator recruitment decreased or was unchanged after E2 treatment (the exception being SRC-3 binding at PTPN13). Our data demonstrate that estrogen stimulation results in the recruitment of ERa and CBP/SRC-3 to specific promoters and enhances the association of RNA Pol II, and these findings agree with previous observations by Klinge et al. (2004) that different ERE sequences modulate the interaction of ligand bound ERa with coactivators.
Next, we correlated the effect of ERa and coactivator(s) binding on changes of chromatin and expression status in these responsive genes. Consistent with the ChIP-chip results, five loci (CCND1, c-MYC, THBS1, RBBP8, and CR2) showed 3-to 15-fold increases of Ac/Me ratios and 2-to 3-fold increases of mRNA levels after E2 treatment ( Figure 5A ). Except for CR2, increased levels of histone acetylation and decreased levels of histone methylation of the target genes usually coincided with the timing (at 3 hr) of ERa binding to their respective promoters. In CR2, the chromatin response was delayed (observed at the 24 hr time point) relative to ERa binding, which may reflect the heterogeneous nature of some responsive loci. It is also possible that the critical region is not located in or near the predicted ERE of the CR2 promoter. Predicted to be downregulated by ChIPchip analysis, the chromatin of BCL11A, PCDH9, and PTPN13 showed an overall decrease in Ac/Me ratios (0.1-to 0.7-fold) after E2 treatment ( Figure 5B ), accompanied by a 2-to 3-fold decrease in their mRNA level. Taken together, these validation studies generally confirm the validity of microarray findings and support the collaborative action of ERa and coactivator(s) binding and chromatin remodeling on these promoters after E2 stimulation.
Computational Modeling Reveals Seven Modules of Combinatorial Control that Predict Transcriptional Activities of Responsive Promoters upon Estrogen Stimulation
The combinatorial theory of gene regulation by transcription factors states that transcription factors act cooperatively to mediate target gene activation (Wasserman and Sandelin, 2004) . Accordingly, the identification of the putative cis-regulatory modules in different sets of responsive promoters enable the discovery of synergistically interacting transcription factors that are involved in crosstalk with the ERa signaling pathway. To identify transcription factor partners involved in the regulation of acetylated and methylated ERa target genes, a computational model that distinguishes these two sets of promoters was constructed by using ERa target promoter sequences from 2220 to +220 bp around the ERE ( Figure 6A ). CART analysis initially identified 20 of the most important transcription factor binding sites (TFBSs) from 140 TFBSs (with at least 35% occurrence in either type of targets) in the TRANSFAC database. A minimal-cost tree was constructed based on these transcription factor binding sites as the categorical predictor variables ( Figure 6B ). The prediction rate, based on 10-fold crossvalidation, was 80% for acetylated targets and 100% for methylated targets. Based on the discovery of overrepresented TFBSs identified by CART, five cis-regulatory modules, i.e., ERE+CRX, ERE+MYB, ERE+c-MYC, ERE+SMAD3, and ERE+E47, were identified for upregulated (i.e., more acetylated) targets, and two modules (ERE+HNF3a and ERE+E47+ETS-1 68) were identified for downregulated (i.e., more methylated) targets ( Figure 6C) . Overall, the bioinformatics analyses identified seven distinct cisregulatory modules for upregulated or downregulated ERa target genes. These results suggest that specific transcription factor partners are involved in the ERa-regulated transcription network.
c-MYC Is a Positive Regulator of ERa-Regulated Transcriptional Activation Next, we experimentally verified the prediction results by CART. In one of the cis-regulatory modules, c-MYC binding sites were found to be located near (13-214 bp) EREs of 13 ERa-responsive promoters ( Figure 7A and Table S4 ). Because c-MYC is an important transcription factor regulated by ERa in breast cancer (Dubik et al., 1987) , we examined the role of c-MYC in ERa-regulated transcriptional activation. First, we determined if c-MYC was recruited to ERa-responsive promoters. Quantitative ChIP-PCR analysis showed that after E2 treatment for 3 hr, a 2-to 4-fold increase of c-MYC binding was seen in 11 of the ERa target genes tested (LOC153364, HK2, RCC2, GABPB2, SYVN1, DLX1, VDP, SAMHD1, RBBP8, CR2, and MEA) ( Figure 7B ). No c-MYC binding was detected in a negative control gene, RASSF1A (data not shown). Because TRRAP functions as a c-MYC-interacting coactivator that mediates histone acetyltransferase recruitment and c-MYCdependent oncogenesis (McMahon et al., 1998; Park et al., 2001) , its association with the same subset of loci was examined. Quantitative ChIP-PCR showed that E2 treatment caused a concordant increase of TRRAP binding at six of the 11 loci (GABPB2, DLX1, VDP, RBBP8, CR2, and MEA) ( Figure 7C ). These data suggest that estrogen stimulation results in the recruitment of c-MYC and the coactivator TRRAP to a subset of ERa-responsive promoters.
The association of TRRAP, which physically interacts with c-MYC (McMahon et al., 1998) and ERa (Yanagisawa et al., 2002), with ERa-responsive promoters containing a c-MYC binding site and ERE in close proximity implies a functional interaction between c-MYC and ERa. We used coimmunoprecipitation assays to examine the association of c-MYC and ERa in the nucleus in response to E2 treatment. Treatment of MCF7 cells with E2 for 3 hr increased the amount of c-MYC in the immunoprecipitated ERa complex ( Figure 7D , upper panel). In the reciprocal experiment, the amount of ERa in the complex immunoprecipitated with the c-MYC antibody was increased after E2 treatment for 1 and 3 hr ( Figure 7D, lower panel) . Consistent with these observations, ERa and c-MYC protein levels in the nucleus were increased at 1 and 3 hr after E2 treatment, as shown by immunoblotting ( Figure S2) .
As predicted by CART, further recruitment of c-MYC to ERa-responsive promoters caused transcriptional activation ( Figure 6C ). To examine if the c-MYC binding site confers estrogen responsiveness, a deletion mutant of the MEA promoter, which contains a c-MYC binding site and ERE (Figure 7A ), was constructed. Estrogen treatment increased the transcriptional activity of the wild-type MEA promoter >2-fold (p < 0.005, Figure 7E ). However, the estrogen responsiveness of the MEA promoter was abolished in the absence of the c-MYC binding site (p < 0.005, Figure 7E ). To further validate ERa and c-MYC coregulation in a subset of ERa-responsive promoters, siRNAs directed against ERa and/or c-MYC were transfected into estrogen-treated MCF7 cells. Quantitative RT-PCR analysis showed a 50% knockdown of ERa mRNA by 48 hr after transfection of ERa siRNA ( Figure 7F ). Interestingly, ERa siRNA treatment also resulted in a 40% knockdown of c-MYC mRNA, further supporting a positive regulatory role of ERa on c-MYC transcription. c-MYC siRNA treatment resulted in a 50% knockdown of c-MYC mRNA. When the cells were simultaneously treated with both siRNAs, ERa and c-MYC mRNA levels were reduced by 50% and 40%, respectively. In all of the 11 ERa-responsive genes that showed increased c-MYC binding (>2-fold) upon E2 treatment ( Figure 7B ), c-MYC siRNA treatment significantly (p < 0.05) reduced their mRNA levels (12% to 57%, data not shown). The mRNA levels of two ERaresponsive genes, RBBP8 and MEA, were decreased (p < 0.05) by individual siRNA treatments ( Figure 7F ). More importantly, combined siRNAs treatment further reduced (p < 0.005) RBBP8 and MEA mRNA levels, indicating that ERa and c-MYC coregulate these responsive targets at the transcriptional level.
Discussion
Estrogen signaling has been intensively studied for the last 20 years, and the complexity of this classical transduction pathway is beginning to be unraveled. The architecture of the estrogen regulatory network can be categorized into single-component and multicomponent inputs. In the single-component input model, downstream target genes are activated or suppressed upon promoter binding of the ERa complex, triggering a cascade of downstream events and forming a regulatory feedback loop for ERa-mediated actions. Perhaps more likely, however, is that estrogen signaling regulates downstream gene activity through the multicomponent inputs. In support of this latter possibility, experimental evidence exists for crosstalk between ERa signaling and multiple transduction pathways, including HER2, PI3K/Akt, IGF-IR, Src, or MAPK (Osborne et al., 2005) . Furthermore, estrogen signaling, which controls the balance of growth and apoptosis in normal breast epithelial cells, becomes disrupted in breast cancer cells, resulting in preferential utilization of these other transduction pathways, contributing to abnormal cell proliferation. Therefore, comprehensive identification and characterization of downstream promoters can provide deeper insight into the hierarchy of ERa-mediated regulatory networks.
In the present study, the ability of ChIP-chip to identify in vivo direct target promoters of a transcription factor has allowed us to define specific targets directed by the ERa regulatory network. Our genome-wide approach used a CpG island microarray to identify 92 putative ERa-responsive promoters. The microarray platform used in this study contains 4500-5000 single-copy CpG promoters (Heisler et al., 2005) , and ERa was found to bind to w2% of the promoters in MCF7 breast cancer cells, a proportion similar to genomic binding of other transcription factors (Odom et al., 2004; Ren et al., 2002) . Because acetylation and dimethylation at histone 3 lysine 9 correlate with gene activation and repression (Kondo et al., 2004; Peters et al., 2003; Peterson and Laniel, 2004; Roh et al., 2005) , respectively, we utilized the same CpG island microarray to determine the histone modification status of ERa target promoters as a surrogate for transcriptional activity. Furthermore, by using an integrated bioinformatics approach, we have identified seven cis-regulatory modules containing combinatorial binding patterns for additional transcription factors in ERa-responsive promoters. These transcription factor partners, including CRX, MYB, c-MYC, SMAD3, E47, HNF3a, and ETS-1, are known to be involved in breast carcinogenesis (Lacroix and Leclercq, 2004; Lincoln and Bove, 2005; Matsuda et al., 2001; Rushton et al., 2003) , consistent with the notion that ERa plays a role in promoting the development of breast cancer cells.
Of the above ERa transcriptional partners, we have demonstrated a previously unknown coregulatory role of c-MYC for a subset of ERa-responsive genes. The c-MYC protein, an important regulator of many cellular processes including proliferation and apoptosis (Pelengaris et al., 2002) , is overexpressed in human breast carcinoma (Berns et al., 1992; Bland et al., 1995) . Our observations that estrogen treatment of MCF7 breast cancer cells results in ERa nuclear translocation, receptor 3 days were transfected with the indicated MEA luciferase reporter constructs and a Renilla luciferase plasmid and treated with or without 10 nM E2 for 24 hr, and the luciferase activity was analyzed. Each error bar represents standard deviation calculated from triplicates. The double asterisk and ++ indicate p < 0.005 (versus untreated and E2-treated wild-type MEA luciferase reporter construct, respectively). (F) ERa and c-MYC coregulate ERa-responsive genes. MCF7 cells were transfected with 25 nM of siRNAs targeting c-MYC and/or ERa. After being hormone-starved for 3 days, the cells were either left untreated or were treated with 10 nM E2 for 3 hr. The expression of c-MYC, ERa, RBBP8, and MEA mRNA was determined by quantitative RT-PCR. Each error bar represents standard deviation calculated from triplicates. The asterisk represents p < 0.05 and the double asterisk indicates p < 0.005 (verses cells treated with E2 only). recruitment to the c-MYC promoter, increased c-MYC gene transcription, and elevated c-MYC protein level in the nucleus are in agreement with a recent report (Park et al., 2005) ; furthermore, we demonstrated estrogen-induced recruitment of c-MYC to certain ERa bound promoters ( Figure 7B and Table S4 ). Notably, as these promoters contain both ERE and c-MYC binding elements located in close proximity to one another, we went on to show that ERa and c-MYC physically interact in MCF7 cells and that estrogen stimulation further enhances the ERa/c-MYC interaction ( Figure 7D ). We speculate that this physical interaction is mediated via bridging factors, including TRRAP, which interact with AF-2 of ERa via LxxLL motifs (Yanagisawa et al., 2002) and with the c-MYC N terminus via a separate domain (McMahon et al., 1998) . In fact, estrogen stimulation increases the association of TRRAP with some of the ERa/c-MYC bound promoters ( Figure 7C ). However, it should also be pointed out that three promoters showed no TRRAP binding ( Figure 7C ), indicating that coactivators other than TRRAP may bridge ERa/c-MYC interaction on these promoters. Previous studies have demonstrated that TRRAP forms a structural core for the assembly and recruitment of histone acetyltransferase complexes involved in transcriptional activation by ERa (Yanagisawa et al., 2002) and c-MYC (Park et al., 2001) . Collectively, these observations are consistent with our findings that estradiol-induced corecruitment of ERa, c-MYC, and TRRAP to ERa-responsive promoters is associated with hyperacetylated H3-K9 and increased transcriptional activity ( Figures 5A, 7E , and 7F). This scenario-the stabilization of ERa-coactivator interactions by adjacent transcription factor partnerscould allow other signal transduction pathways to finetune ERa-mediated transcription.
In summary, we have taken an integrated, genomewide approach to define complex networks directed by ERa. Our results indicated that a physical interaction between ERa and c-MYC is needed for activation of a subset of ERa-responsive promoters. This action may orchestrate the growth of breast cancer cells in response to the mitogenic estrogen signal. This finding exemplifies the power of combining both experimental and bioinformatics methods to identify regulatory elements in complex signaling networks. Our integrative approach should be broadly applicable to the elucidation of regulatory networks of other transcription factors.
Experimental Procedures
Reagents and Antibodies 17b-estradiol (E2), aminoallyl-dUTP, and formaldehyde were purchased from Sigma (St. Louis, MO). Culture media and fetal bovine serum (FBS) were obtained from Invitrogen (Carlsbad, CA) and Hyclone (South Logan, UT), respectively. The antibodies used in chromatin immunoprecipitation are as follows and were purchased from Santa Cruz Biotechnology (Santa Cruz, CA): ERa (D-12), c-MYC (N-262), , CBP (C-20), , and TRRAP (T-17). The antibodies against acetyl-K9 of histone 3 (AcH3K9, 06-942) and dimethyl-K9 of histone 3 (diMeH3K9, ab-7312) were obtained from Upstate Biotechnology (Lake Placid, NY) and Abcam (Cambridge, MA), respectively.
Chromatin Immunoprecipitation Microarray MCF7 cells were maintained in minimum essential medium (MEM) supplemented with 10% FBS, 100 units/ml penicillin/streptomycin, 2 mM L-glutamine, 6 mg/ml insulin, and 0.4 mM HEPES. The cells were hormone-starved for 4 days in phenol-red free MEM supplemented with 3% charcoal-dextran-treated FBS followed by treatment with 17b-estradiol (E2; 10 nM) for 0, 3, 12, and 24 hr. Two millions cells were crosslinked with 1% formaldehyde for 12 min, and chromatin immunoprecipitation was performed by using a ChIP assay kit (Upstate Biotechnology) as described previously . Incorporation of aminoallyl-dUTP into 2 mg ChIP-DNA, control no-antibody DNA, or input DNA was conducted with the BioPrime DNA Labeling System (Invitrogen). Cy5 and Cy3 fluorescent dyes (Amersham, Buckinghamshire, UK) were coupled to ChIP/no-antibody DNA and input DNA, respectively, and were cohybridized to two microarray platforms. Chromatin landscaping microarray contains four ERa-responsive promoter regions, each spanning 5 kb upstream and 1 kb downstream from the transcription start sites of these genes. For each gene, a 6 kb region was covered by 12 DNA fragments with an average size of 500 bp, designated as promoter 1 to promoter 10 (P1-P10) and exon 1 to exon 2 (E1-E2). These fragments and 16 control repetitive sequences were amplified by PCR and spotted in triplicate to UltraGAPS-coated slides (Corning, Acton, MA) by using the Affymetrix GMS 417 Arrayer (Affymetrix, Santa Clara, CA). The spotted slides were UV crosslinked and stored in a desiccator.
For global analysis, dye-coupled DNA was also hybridized onto microscopic slides containing 12,192 arrayed DNA fragments (http://data.microarrays.ca/cpg/; Heisler et al., 2005) . Microarray hybridization and posthybridization washes have been described previously (Kondo et al., 2004; Yan et al., 2001) . The washed slides were scanned by a GenePix 4000A scanner (Axon, Union City, CA), and the acquired microarray images were analyzed with GenePix Pro 6.0 software (Axon). Two independent experiments were performed for each time point treatment and antibody.
Statistical Analysis
After excluding the spots flagged for bad quality, signal ratios were log 2 transformed and normalized by using intensity-dependent normalization (Yang et al., 2002) . In order to identify putative ERa targets, the loci were first filtered by SAM analysis (Tusher et al., 2001 ) by using multiclass comparison with four E2 treatment time points (0, 3, 12, and 24 hr). The target loci were then identified by a signal ratio cutoff of 2 at the 3 hr time point in both independent experiments. To identify acetylated and methylated loci among the putative targets in the ChIP-chip experiments with antibodies against acetyl-and dimethyl-H3-K9, SAM analysis was performed on the 92 target loci as a two-class unpaired time course.
Quantitative ChIP-PCR To confirm candidate ERa target genes determined by ChIP-chip, PCR primers targeting a region within 200 bp of the predicted ERE were used to measure the amount of this sequence in anti-ERa-immunoprecipitated samples by quantitative PCR with SYBR Greenbased detection (Applied Biosystems, Foster City, CA). Experimental quantitative ChIP-PCR values were normalized against values obtained by a standard curve (50 to 0.08 ng, 5-fold dilution, R 2 > 0.99) constructed by input DNA with the same primer set. The same method was used to determine binding levels of other factors and enrichment levels of histone modifications. For some target genes (BCL11A, PCDH9, and PTPN13) in which the predicted ERE is located >2 kb upstream of the TSS, additional primers, targeted to a region within 500 bp of the TSS, were designed to measure histone modifications. Specific primers for amplification are available upon request.
RNA Extraction and Quantitative RT-PCR
Total RNA was prepared from sampled cells by the TriZol reagent (Invitrogen). Two mg RNA was treated with DNase I (Invitrogen) to remove potential DNA contamination and then was reverse transcribed with SuperScript II reverse transcriptase (Invitrogen). Quantitative RT-PCR was performed by using SYBR Green (Applied Biosystems) as a marker for DNA amplification on a 7500 RealTime PCR System apparatus (Applied Biosystems). The relative mRNA level of a given locus was calculated by relative quantitation of gene expression (Applied Biosystems) with GAPDH or b-actin mRNA (based on amplification efficiency) as an internal control.
Statistical analyses were carried out by using a two-tailed t test. Specific primers for amplification are available on request.
RNA Interference MCF7 cells (2.5 3 10 5 ) were seeded in a 6 well plate and cultured in phenol-red free MEM supplemented with 3% charcoal-dextrantreated FBS overnight. The next day, cells were transfected with predesigned siRNAs against c-MYC (catalog number 143591, Ambion, Austin, TX) and/or ERa (catalog number M-3401, Upstate Biotechnology) at 25 nM by using TransIT-TKO transfection reagent (Mirus, Madison, WI) according to the manufacturer's protocol. After 2 days, the cells were treated with or without 10 nM E2 for 3 hr, and then total RNA was harvested for quantitative RT-PCR analysis, as described above.
Coimmunoprecipitation MCF7 cells were hormone-starved for 3 days and then treated with 10 nM E2 for the indicated time periods. Nuclear extracts were prepared with a Nuclear Extract Kit (Active Motif, Carlsbad, CA) and diluted to 1 mg protein/ml with buffer containing 50 mM Tris-HCl and 150 mM NaCl. Nuclear extracts (0.5 mg) were precleared with protein G agarose (30 ml) for 30 min and incubated overnight with anti-c-MYC (1 mg; 9E10, Santa Cruz), anti-ERa (1 mg, Ab-10, Lab Vision Corporation, Fremont, CA), or rabbit IgG (1 mg; Santa Cruz). Immunocomplexes were precipitated with protein G agarose (50 ml) for 1 hr and washed three times with buffer containing 50 mM Tris-HCl, 150 mM NaCl, and 1% NP40. The immunoprecipitated proteins were dissolved in 20 ml SDS-PAGE loading buffer and subjected to immunoblotting analysis with the indicated antibodies.
Transfection and Luciferase Assay
The upstream promoter region (2303 to +472 bp) of MEA, including the c-MYC binding site and ERE located at 212 and +155 bp, respectively, was cloned into the luciferase reporter plasmid pGL3 (Dual-Luciferase Reporter Assay System, Promega Corporation, Madison, WI). The c-MYC binding site deletion mutant (pGL3-MEADc-MYC) was then generated by site-directed mutagenesis (QuikChange II XL Site-Directed Mutagenesis Kit, Stratagene, La Jolla, CA) and verified by DNA sequencing. MCF7 cells that were hormone-starved for 3 days at 70% confluence were transfected with 1mg of the indicated luciferase reporter constructs and 60 ng of Renilla luciferase plasmid by using Superfect Transfection Reagent (Qiagen, Hilden, Germany) in 6 well plates. The cells were then treated with or without 10 nM E2 for 24 hr, and luciferase activity was analyzed. Luciferase activity was normalized by Renilla value and represented as fold activation relative to the activity obtained by the pGL3 basic construct alone.
Computational Modeling
The OMGProm database was used to retrieve promoter sequences of orthologous pairs for the candidate ERa target genes identified by ChIP-chip. The program ERTarget, developed previously by us , was used to identify the direct ERa targets by analyzing the promoter sequences. Briefly, the ERTarget program discriminates direct ERa target promoters from nontargets by scanning for ERE and combinatorially associating other TFBSs conserved in human-mouse orthologous promoters. We used a similar approach to discriminate acetylated ERa target promoters from methylated ERa target promoters. CART (Breiman et al., 1984) analysis was employed to classify acetylated and methylated ERa target promoters. The resulting model was a highly interpretable decision tree for cis-regulatory modules identification. Because CART is a relatively unstable regression method with high variance, further experiments were needed to verify the prediction (see also the Supplemental Data for detailed CART description). All possible TFBSs predicted by MATCH (Kel et al., 2003) using the position weight matrices (PWM) from the TRANSFAC database (Wingender et al., 2000) were considered as binary predictor variables, either 1 or 0, depending on presence or absence within a 2220 bp to +220 bp region of a predicted ERE (see Equation 1, Figure 6A ). A distance of 220 bp is the approximate distance between adjacent nucleosomal linkers and the optimal distance for short-range looping in chromatin (Ringrose et al., 2003) . The ''Gini'' method was selected as the splitting method for growing the tree, and the 10-fold cross validation method was used to obtain the minimal tree (see Equation 2 ). The analysis was performed on the commercially available CART software (Salford Systems, San Diego, USA) and used the following equations:
Where D is a collection of TFs; y i is the class label for acetylated (equal to 1) and methylated (equal to 0) promoters; x ik is the binary value of TF k that represents presence (equal to 1) or absence (equal to 0) of its binding site within the neighborhood of ERE; N is the number of promoters; M is the number of TFs. For a node t and classes (1,., k), Gini index is defined as:
Where P(j/t) is the relative part of class j at node t. 
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